Articles On Opthea (ASX:OPT)

The journey of each individual medical treatment from idea to market requires the involvement of multiple parties big and small. The general consensus seems to be that it takes a big player to get a drug to market, which more often than not...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 134-odd small cap health stocks and of those which were trading on Wednesday, 71 were in positive territory over the last fortnight, 11 were flat and 52 saw...

As a sector, healthcare has provided some of the strongest returns over the past year. The S&P/ASX 200 Health Care Index (ASX: XHJ) has returned more than 26% over the last 12 months, comfortably outperforming the benchmark indexes for...

Having now proven its drug works on two eye diseases, Opthea (ASX:OPT) is looking to future treatment options. The immediate consideration for Opthea is a phase three study on Diabetic Macular Edema (DME), similar to its planned phase three...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Australian company Opthea (ASX:OPT) has announced topline results from a trial evaluating its biologic OPT-302 in combination with Bayer's PBS-listed EYLEA (aflibercept).

10 months since Opthea’s (ASX:OPT) drug proved itself against wet-AMD, it’s passed another clinical trial against Diabetic macular edema (DME). This morning the company conducted a 144 patient phase 2a clinical trial against DME. While it i...

Has Opthea’s (ASX:OPT) clinical trial of its drug against Diabetic macular edema (DME) been as successful as last year’s wet-AMD trial? We’re less than 24 hours from finding out. The company entered a trading halt this morning pending the r...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week As markets...

If exciting small cap ASX shares like Whispir Ltd (ASX: WSP) are too small for your tastes, then you might want to have a look at the mid cap side of the market. At this side of the market I believe there are a number of shares which have...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Want to know which stocks the fund managers have been putting their money in (and out) of? We’ve been keeping track so you don’t have to. Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last f...

Healthcare is not the favourite child it was at the start of the COVID-19 pandemic, but one index measuring the sector is still up on the wider market. Biotech Daily’s top 40 index is up 14 per cent over the last month, compared to 4 per ce...

The ASX is home to a small but vibrant and growing biotechnology sector. There are a number of providers that are making significant inroads on a global scale. Here we examine 3 ASX biotech shares that have all seen strong share price rise...

The Australian drugs regulator has told sponsors of 10 products to stop marketing them for macular degeneration, a prevalent but difficult to treat eye condition affecting the elderly. Following reviews that began in 2017, the Therapeutic G...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Markets be...

Last year was a solid year for many ASX stocks and 2020 was also looking pretty good until COVID-19 struck the markets in late February. Earlier this week Reuben Adams recapped which of last year’s top mining and exploration companies have...

The Australian share market is home to a large number of mid cap shares. The good thing about this is that mid caps generally carry less risk than small caps, but stronger potential returns than large caps. This arguably makes it one of th...

Special Report: Drug developer Dimerix hasn’t been affected by the March market rout and since April has surged. What is behind this push? Shares in drug developer Dimerix (ASX:DXB) have doubled in value in the last six months and the stock...

After performing very strongly in 2019, the All Ordinaries index has given back all its gains and more in 2020. This means the index is now down a disappointing 17.2% since this time in 2019. The good news is that not all shares have given...

The S&P/ASX 200 Index (ASX: XJO) has come under significant pressure over the last couple of months due to the coronavirus pandemic. Whilst this is disappointing, one positive is that it has brought some top shares down to attractive l...

Due to populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to rise. I expect this trend to continue for several decades, which could make the healthcare sector a great...

One side of the share market which I think is a great place to look for investment ideas is the mid cap space. I like this side of the market because it offers stronger potential returns than the large cap side of the market, but arguably...

After a disappointing 43% decline in March, the Afterpay Ltd (ASX: APT) share price has started the month of April on a very positive note. In afternoon trade on Wednesday the payments company’s shares are up 6% to $19.99. Why did the Afte...

At lunch on Tuesday the S&P/ASX 200 Index (ASX: XJO) has continued its positive run and is charging notably higher. The benchmark index is up 2.7% to 5,321.7 points at the time of writing. Here’s what is happening on the market today:...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on course to record another strong gain. At the time of writing the benchmark index is up 3.15% to 5,345.2 points. Four shares that are climbing more than most today are listed...

Clinical stage biopharmaceutical company Opthea (ASX:OPT) says it has completed patient dosing and all follow-up week 12 patient visits in the Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination...

The Opthea Ltd (ASX: OPT) share price could be one of the biggest bargains on the ASX according to one leading broker. Incredibly, this is despite the shares of the developer of novel biologic therapies for the treatment of eye diseases be...

Here it is – your weekly look at the stocks fund managers are buying (and selling). Trading Places is Stockhead’s recap of substantial holder movements among ASX small caps in the last week. Substantial shareholders are shareholders holding...

The ASX healthcare sector continues to be one of the top performers on the ASX in terms of share price rises over the past 12 months, despite all the strong market correction. While most Australians are likely familiar with healthcare comp...

At the turn of the millennium Megan Baldwin, high flying CEO of ophthalmology biotech Opthea (ASX:OPT), had a decision to make: did she take a promising job in Australian academia or leap into the hotbed of innovation, San Francisco, for th...

Last year the ASX’s biotechs began kicking goals they’d promised years ago, as small caps from eye disease curer Opthea (ASX:OPT) to breast density imager Volpara (ASX:VHT) launched their way into the collective consciousness. The biotechs...

Due to populations around the world getting older and chronic disease burden increasing, demand for healthcare services continues to rise. I believe this trend will continue for several decades, which could make the healthcare sector a gre...

In an industry where CEOs rise and fall on the outcomes of their clinical trials, Megan Baldwin is still ascending. Baldwin, CEO of ophthalmology biotech Opthea (ASX:OPT), became a famous name in biotech last year after the company leapt fr...

One of the areas of the market that I’m most bullish on is the healthcare sector. Thanks to a number of favourable tailwinds, I believe the sector is well-positioned for solid growth over the next few decades. But which shares should you b...

Growing ASX-listed biotech company Paradigm Biopharmaceuticals Ltd (ASX: PAR) has performed strongly over the last year, with Paradigm shares skyrocketing more than 250% higher to $4.20 as at the time of writing. This means it has outperf...

The Opthea Ltd (ASX: OPT) share price has already surged over 20% higher in January to $3.60 as at the time of writing. Although the 52-week high of $4.15 the biotechnology company hit back in September still seems like a little way off ye...

If you’re interested in investing in the mid cap side of the market then you’re in luck. At this side of the market I believe there are a good number of shares that have the potential to grow strongly over the next decade. Three mid cap AS...

Earlier today I looked at how successful small cap investing can be if you can identify a start of the future. With that in mind, I thought I would pick out several small cap shares which I believe have significant potential and could gene...

Australian clinical-stage biopharmaceutical company Opthea (ASX:OPT) says it has completed patient recruitment into the phase 2a trial evaluating the safety and efficacy of its OPT-302 administered in combination with Bayer's EYLEA...

Over the last 12 months the Opthea Ltd (ASX: OPT) share price has been one of the best performers on the All Ordinaries index. During this time the shares of the developer of novel biologic therapies for the treatment of eye diseases have...

In 2019 the culmination of decades worth of work turned several biotechs and life sciences companies into overnight successes. As investors look to defensive growth stocks to compensate for a sluggish economy and with expectations of more h...

Over the last decade the healthcare sector has been a great place to investment your money. During this time the S&P/ASX 200 Health Care index has almost quadrupled in value. Whilst I’m not expecting the same level of outperformance ov...

In afternoon trade the S&P/ASX 200 index is pushing notably higher. At the time of writing the benchmark index is up 1.2% to 6,814.7 points. Four shares that are climbing more than most today are listed below. Here’s why they are storm...

The Opthea Ltd (ASX: OPT) share price has been a positive performer on Tuesday morning. At the time of writing the clinical stage biopharmaceutical company’s shares are up almost 2% to $2.98. Why is the Opthea share price pushing higher? I...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

It’s been a good year for healthcare shares in 2019. Led by CSL Limited (ASX: CSL), the S&P/ASX 200 Healthcare Index (ASX: XHJ) is up over 42% for the year. We take a look at 3 ASX healthcare shares that have delivered healthy returns...

On Christmas Day I picked out 10 top ASX shares that I think could be great options for investors in 2020. But they weren’t the only shares that I would be buying right now. Here are 10 more top ASX shares to own in 2020: Nearmap Ltd (ASX:...

The year is nearly over, so I think it’s time to look back at some of the shares that could be called shares of the year. A special shout-out must go to Avita Medical Ltd (ASX: AVH) and Opthea Ltd (ASX: OPT) as two of the best performers o...

I think the Australian share market is home to a large number of small cap shares that have the potential to grow materially larger in the future. While history shows that not all small caps deliver on their potential, I think many of thes...